STOCKS TELEGRAPH

Tag: TherapeuticsMD

  • 3 Stocks You Shouldn’t Ignore: TherapeuticsMD (TXMD), Cardiol Therapeutics (CRDL), Actinium Pharmaceuticals (ATNM)

    3 Stocks You Shouldn’t Ignore: TherapeuticsMD (TXMD), Cardiol Therapeutics (CRDL), Actinium Pharmaceuticals (ATNM)

    Market participants are closely monitoring companies that demonstrate a combination of strong development pipelines and improving financial indicators. In an environment where data-driven decisions are key, stocks supported by measurable progress and clear milestones are gaining traction among both retail and institutional investors.

    TherapeuticsMD Inc (TXMD)

    TherapeuticsMD Inc (NASDAQ: TXMD) flaunted slowness of -0.97% at $2.05, as the Stock market unbolted on April 13, 2026. During the day, the stock rose to $2.13 and sunk to $1.97. Taking a more long-term approach, TXMD posted a 52-week range of $0.86-$2.95.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 72.84%. Meanwhile, its Annual Earning per share during the time was 72.84%.  This publicly-traded company’s shares outstanding now amounts to $11.57 million, simultaneously with a float of $11.39 million. The organization now has a market capitalization sitting at $23.73 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is gaining attention for its potential to deliver disease-modifying therapies in cardiovascular medicine by targeting inflammation at its biological source. This approach is increasingly supported by scientific research linking immune system activation to structural heart damage and long-term disease progression.

    Market Momentum

    As of April 13, 2026, CRDL closed at $1.3600, down 1.45%, with trading volume (243,619 shares) well below its average of 589,930 shares—indicating reduced near-term activity. With a market cap of $151.885M, the stock remains within its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.48 continues to point toward significant upside potential, reflecting confidence in upcoming clinical milestones.

    Clinical Evidence: Myocarditis Program

    The Phase II ARCHER trial evaluated CardiolRx™ in acute myocarditis, a condition that can lead to heart failure or sudden cardiac death, particularly in younger patients. Results showed meaningful reductions in left ventricular (LV) mass, a key marker of cardiac remodeling. This suggests that the therapy may contribute to structural recovery, not just inflammation control.

    Clinical Relevance

    The ability to demonstrate improvements in cardiac structure is notable in a field where most therapies focus on symptom management. These findings support the broader hypothesis that targeting inflammation can alter disease progression, potentially opening new treatment pathways in cardiovascular care.

    Outlook

    If further validated, Cardiol’s myocarditis program could expand beyond niche indications into broader cardiovascular applications, strengthening the company’s long-term growth potential.

    Actinium Pharmaceuticals Inc (ATNM)

    Witnessing the stock’s movement on the chart, on April 13, 2026, Actinium Pharmaceuticals Inc (AMEX: ATNM) set off with pace as it heaved 2.78% to $1.11. During the day, the stock rose to $1.11 and sunk to $1.06. Taking a more long-term approach, ATNM posted a 52-week range of $0.95-$1.95.

    The Healthcare sector firm’s twelve-monthly sales growth has been 9.91% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 9.91%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.74%. This publicly-traded company’s shares outstanding now amounts to $31.20 million, simultaneously with a float of $30.40 million. The organization now has a market capitalization sitting at $34.82 million.

  • FDA’s Response: TherapeuticsMD Inc. (TXMD) Plummets Further Aftermarket

    TherapeuticsMD Inc. (TXMD) stock extended losses by 5.41% aftermarket when the company announced FDA’s response. The FDA declined TXMD’s Annovera’s previously submitted sNDA.

    During regular trading, the stock lost 3.30% at a volume of 4.71 million, closing the session at $0.4510. Following the announcement, the stock plunged further down to reach $0.4266 in the after-hours at 431.79K shares.

    The current market capitalization of TXMD is $191.64 million with its 424.93 million outstanding shares.

    FDA’s Response to TXMD

    On December 10, the company announced the response of the FDA to some manufacturing testing limits for ANNOVERA. The company had previously submitted an sNDA with the FDA for this purpose. As per the announcement, FDA did not approve the company’s revisions in the sNDA. Further, the FDA requested additional information and also suggested some recommendations.

    TXMD’s Annovera is the only long-lasting, reversible, procedure-free birth control, approved in August 2018 by the FDA. The president of TXMD said in the announcement that Annovera’s supply will be continued under existing specifications. Furthermore, the company will continue working with the FDA regarding the revisions.

    U.S. Patent Litigation with Amneal

    Previously, TXMD announced the settlement of U.S. litigation for Bijuva® with Amenal, on December 08. As per the previous announcement, the company was under patent litigation with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC.

    According to the announcement, TXMD granted a license to Amneal for the commercialization of a generic version of Bijuva in the U.S. This will start on May 25, 2032, with earlier commencement under specific circumstances. Further, TXMD’s last patent for Bijuva with FDA is set to expire on November 21, 2032.

    In addition, this litigation was pending in the U.S. District Court for New Jersey District since the year 2020.

    TXMD’s Financials

    On November 11, TXMD announced its financial results for the third quarter of 2021. As per the Q3 of 2021, the total net products revenue was $25.4 million. This shows an increase of 41.1% from the year-ago quarter.

    Moreover, the company incurred a net loss of $47.4 million in the third quarter of 2021, against $32.6 million in Q3 of 2020. Consequently, the net loss per basic and diluted share was $011 in Q3 of 2021, against $0.12 in the year-ago quarter.

  • TherapeuticsMD Inc. (TXMD) stock soared in the pre-market trading session: here’s why

    TherapeuticsMD Inc. (TXMD) stock recently traded in the premarket at $1.57 which is an 18.94% rise. TXMD’s stock closed at $1.32 which is the same price to its prior session close thus a 0.00% change. The number of shares that exchanged hands in the day was 6.57 million. However, this was lower than the average daily volume of 17.1 million shares within the past 50 days. The volume in the past week was down by -1.49%. TXMD stock has risen by 47.67% in the last 12 months but shed -17.50%. In the last 3 months, it then gained 2.33%. Furthermore, the company’s current market share values at $493.52 million and its outstanding shares stood at 286.69 million.

    The recent positive movement of TXMD stock in the recent pre-market trading session has come adjacent to the press release by the Company announcing approval of its Hormone Replacement Therapy (HRT)

    TherapeuticsMD healthcare provides special care for women

    TherapeuticsMD, Inc. is a healthcare company which is focused towards the production of novel and unique products. These healthcare products are made specifically for women and innovation comes through the design and accordance with the unmet needs/challenges of women. The company looks at various experiences and stages of a woman’s life to keep in mind while designing these products especially for menopause, family planning and reproductive health.

    Approval of HRT capsule, BIJUVA® in UK and BIJUVE®in Belgium.

    TherapeuticsMDInc (TXMD) along with its collaborating partner Theramex announced the approval of BIJUVE® Capsules in the United Kingdom and under the trade name BIJUVA® in Belgium. Theramex is a global specialty pharmaceutical company and like TXMD stock it is dedicated to women’s health. Its vision is to be a lifetime partner for women and has a portfolio of contraceptive, fertility, menopause, and osteoporosis related products covered under established brand names.

    United Kingdom and Belgium are not the first countries where the Hormone Replacement Therapy has been released; USA had BIJUVA made commercially available in April 2019, while Canada and Israel have these commercially available as well. However BIJUVA is Europe’s first and only oral HRT with bio-identical hormones; specifically Estradiol and micronized Progesterone made available.

    Theramex signed an exclusive licensing and supply agreement with TherapeuticsMD Inc. in June 2019, to make BIJUVA available outside of these countries, especially in the European market. This agreement states Theramex paying TherapeuticsMD, certain royalties and milestone fees based upon aggregate net sales.

    The approval in European countries is a major positive move for TXMD stock

    The process of regulatory approval was a decentralized procedure that took place in February and afterwards each country has its own terms and conditions for medical approval. The approval for other significant EU countries will take place shorty, as expected by Theramex. It is possible to see a positive trend of TXMD stock maintain for longer period if commercial availability and approvals come further down the year.